EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.


Journal

Experimental oncology
ISSN: 2312-8852
Titre abrégé: Exp Oncol
Pays: Ukraine
ID NLM: 101230541

Informations de publication

Date de publication:
08 2022
Historique:
entrez: 14 8 2022
pubmed: 15 8 2022
medline: 17 8 2022
Statut: ppublish

Résumé

Renal cell carcinoma (RCC) is one of the most common solid tumors in adults. There is a lack of reliable prognostic and predictive biomarkers for RCC course. Dysregulation of miRNAs expression has been reported to be involved in RCC progression. However, the data on miRNAs expression patterns in tumors are controversial. To investigate the expression and clinical significance of miR-99b, -144, -155, -210, -222, -302а, -377 in RCC ex vivo. Retrospective analysis of the expression levels of miRNAs -99b, -144, -155, -210, -222, -302а, -377 in tumor tissue of 126 patients with clear cell RCC was performed using quantitative polymerase chain reaction. Overexpression of miR-99b, -222, -302a and low levels of miR-155 in RCC tissues were significantly associated with advanced tumor stage (p < 0.05). In majority of patients with distant metastases (> 60%), high levels of miR-99b and 377 were detected (p < 0.05). High/low miR-99b, -144, -155, -210, -222, and -302a ratio was significantly associated with Fuhrman grade of tumors. Aberrant expression of miR-99b, -144, -155, -210, -222, -302а, -377 is strongly associated with advanced RCC, and panel of these miRNAs may be a useful prognostic marker for RCC course.

Identifiants

pubmed: 35964649
pii: 17883
doi: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17883

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-136

Auteurs

Yu Vitruk (Y)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

T Borikun (T)

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine.

O Rossylna (O)

Clinic for Personalized Diagnostics and Therapy Design "Oncotheranostics", Kyiv 03022, Ukraine.

T Zadvornyi (T)

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine.

S Semko (S)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

O Voylenko (O)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

O Stakhovsky (O)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

A Shipko (A)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

E Stakhovsky (E)

National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine. uvitruk@ukr.net

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH